EUVIMEDOtkrijte EUVIMED
CrossrefInformacijska kartica

Coagulation testing in green iguanas ( Iguana iguana ) with development of prothrombin time assays using reptile and avian thromboplastin

Izidora Sladakovic, Benjamin M. Brainard, Stephen J. Divers, Marjory B. Brooks

Journal of Veterinary Emergency and Critical Care · 2022-09 · 32 (5) · 685-689

DOI: 10.1111/vec.13201 ↗
SažetakBibliografski podaci

Sažetak

Abstract Background Captive reptiles often present with clinical signs suggestive of a clotting disorder or severe illness that can induce or exacerbate a coagulopathy. However, coagulopathies in reptiles are difficult to characterize due to lack of species‐appropriate reagents to perform coagulation tests. The objective of this study was to develop screening tests to evaluate the extrinsic and common pathways of coagulation in green iguanas ( Iguana iguana ). Key Findings Reptile and avian thromboplastin, extracted from reptile and avian brains, respectively, were used to initiate coagulation in prothrombin time (PT) assays and commercially available reagents were used to determine Russell's viper venom time, thrombin time, and fibrinogen using the Clauss method. Coagulation assays were performed on citrate‐anticoagulated plasma from 18 healthy green iguanas. Results were summarized as median (minimum–maximum): PT (reptile thromboplastin), 34.8 seconds (27.1–42.1 s), PT (avian thromboplastin), 78.5 seconds (51.6–114.23 s), Russell's viper venom time, 56.15 seconds (18.4–79.7 s), thrombin time, 10 seconds (7.0–36.5 s), and fibrinogen, 258 mg/dl (89–563.0) (2.58 [0.89–5.63 g/L]). Significance Commercial reagents can be used to evaluate the common pathway and fibrinogen; however, avian‐ or reptile‐sourced thromboplastin is preferred for a reliable coagulation trigger to perform the PT assay and evaluate the extrinsic pathway.

Znanje koje odgovara vašem radu.

Od besplatnog početka i osobnog pretraživanja literature do potpunog paketa Research Suite.

Prikaži tarife →

Jesu li uključeni svi cjeloviti tekstovi izdavača?

Ne. Bibliografski zapisi, sažeci i cjeloviti tekstovi različiti su sadržaji. Hoće li cjeloviti tekst biti dostupan ovisi o izvoru, Open Accessu i vašim postojećim licencama. Tarifa EUVIMED ne zamjenjuje dodatna izdavačka prava.

Prikaži tarife →